Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterCorrespondence

Drs. Carter and Do reply

Kaylene L. Carter and Diana V. Do
The Journal of Rheumatology January 2021, 48 (1) 151; DOI: https://doi.org/10.3899/jrheum.200913
Kaylene L. Carter
1Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine, Stanford, California;
2Department of Internal Medicine, Tower Health Reading Hospital, Reading, Pennsylvania, USA.
MD
Roles: Resident Physician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kaylene L. Carter
Diana V. Do
1Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine, Stanford, California;
MD
Roles: Professor of Ophthalmology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Dianado@stanford.edu
  • Article
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

To the Editor:

We thank Dr. Martin-Iglesias, et al for their comments1 on our recent case report published in The Journal2. We reported on a case of hydroxychloroquine (HCQ) retinopathy, and showcased the characteristic optical coherence tomography (OCT) and fundus autofluorescence imaging findings in a patient who had been taking approximately 13.6 mg/kg/day for 8 years, almost triple the recommended dose.

Ethics board approval is not required because this is a single case report and no intervention had been made for research. The patient gave written informed consent to publish the material.

HCQ retinopathy is rare at 0.33% incidence with short-term therapy (< 5–7 yrs)3, especially when treatment follows the American Academy of Ophthalmology (AAO) guideline of doses ≤ 5 mg/kg/day4. Dr. Martin-Iglesias, et al1 emphasize the point that there is increased risk of toxicity among patients receiving greater doses. In a prior study from this group following a cohort receiving HCQ at ≤ 5 mg/kg/day, no clinically significant retinal changes or cases of toxicity were detected by OCT over a 5-year period5. These findings align with the AAO-recommended HCQ dosage guideline.

However, duration of therapy relative to daily dose also plays a significant role and is considered a critical factor when screening for HCQ retinopathy4. After 10 years of daily HCQ use within the 4–5 mg/kg range, risk of retinopathy increases dramatically6. It would be interesting to further follow the study cohort for retinal changes at the decade timepoint and beyond.

Overall, we highlight the comment of Dr. Martin-Iglesias, et al1 that HCQ retinal toxicity is most dependent on daily dose. For those on a high dose, or long-duration HCQ therapy, it is especially important to have regular ophthalmologic screenings.

REFERENCES

  1. 1.↵
    1. Martin-Iglesias D,
    2. Artaraz J,
    3. Ruiz-Irastorza G.
    Hydroxychloroquine retinal toxicity and its association with dosage. J Rheumatol 2021;48:150-1.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Carter K,
    2. Do D.
    Hydroxychloroquine-induced retinal toxicity. J Rheumatol 2020;47:632.
    OpenUrlFREE Full Text
  3. 3.↵
    1. Wolfe F,
    2. Marmor M.
    Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res 2010;62:775-84.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Marmor M,
    2. Kellner U,
    3. Lai Y,
    4. Melles R,
    5. Mieler W.
    American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 2016;123:1386-94.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Martín-Iglesias D,
    2. Artaraz J,
    3. Fonollosa A,
    4. Ugarte A,
    5. Arteagabeitia A,
    6. Ruiz-Irastorza G.
    Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus. Lupus 2019;28:555-9.
    OpenUrl
  6. 6.↵
    1. Melles RB,
    2. Marmor MF.
    The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014;132:1453–60.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 48, Issue 1
1 Jan 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Drs. Carter and Do reply
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Drs. Carter and Do reply
Kaylene L. Carter, Diana V. Do
The Journal of Rheumatology Jan 2021, 48 (1) 151; DOI: 10.3899/jrheum.200913

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Drs. Carter and Do reply
Kaylene L. Carter, Diana V. Do
The Journal of Rheumatology Jan 2021, 48 (1) 151; DOI: 10.3899/jrheum.200913
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Dr. Yoshida et al reply
  • A Rare Case of Parvovirus B19-Induced Atlantoaxial Arthritis
  • Dr. Solomon et al reply
Show more Correspondence

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire